Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,
Open accessThe DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.
Abstract
Specific interactions of human melanocortin-4 receptor (hMC4R) with its nonpeptide and peptide agonists were studied using alanine-scanning mutagenesis. The binding affinities and potencies of two synthetic, small-molecule agonists (THIQ, MB243) were strongly affected by substitutions in transmembrane alpha-helices (TM) 2, 3, 6, and 7 (residues Glu(100), Asp(122), Asp(126), Phe(261), His(264), Leu(265), and Leu(288)). In addition, a I129A mutation primarily affected the binding and potency of THIQ, while F262A, W258A, Y268A mutations impaired interactions with MB243. By contrast, binding affinity and potency of the linear peptide agonist NDP-MSH were substantially reduced only in D126A and H264A mutants. Three-dimensional models of receptor-ligand complexes with their agonists were generated by distance-geometry using the experimental, homology-based, and other structural constraints, including interhelical H-bonds and two disulfide bridges (Cys(40)-Cys(279), Cys(271)-Cys(277)) of hMC4R. In the models, all pharmacophore elements of small-molecule agonists are spatially overlapped with the corresponding key residues (His(6), d-Phe(7), Arg(8), and Trp(9)) of the linear peptide: their charged amine groups interact with acidic residues from TM2 and TM3, similar to His(6) and Arg(6) of NDP-MSH; their substituted piperidines mimic Trp(9) of the peptide and interact with TM5 and TM6, while the d-Phe aromatic rings of all three agonists contact with Leu(133), Trp(258), and Phe(261) residues.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They concluded that the HFRW sequence of NDP-MSH was required to form a β-hairpin-like structure so that the phenyl ring of Phe 7 interacts with the indole ring of Trp 9 (Figure 3B).”
From ACTH Antagonists (2016) · cites this paper as [41]
Citations
Cites
CHARMM: A program for macromolecular energy, minimization, and dynamics calculations
Brooks, B. R., Bruccoleri, R. E., Olafson, B. D., States, D. J., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 14,944 · cited 1×
“Final energy minimization of all hMC4R-agonist complexes was performed using the CHARMm (45) potential with ε=10, and using the adopted-basis NewtonRaphson method (50 iterations).”
MethodCrystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637 · cited 2×
“However, among all GPCRs, a crystal structure has been determined only for rhodopsin, and only in its inactive state (23,24).”
BackgroundBallesteros, J. A., & Weinstein, H. (1995) · Methods in Neurosciences · doi:10.1016/s1043-9471(05)80049-7 · Cited by 2,999
Principles of docking: An overview of search algorithms and a guide to scoring functions
Halperin, I., Ma, B., Wolfson, H., & Nussinov, R. (2002) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.10115 · Cited by 1,294 · cited 1×
“Finally, ligand docking is a complicated problem (28).”
BackgroundRequirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin
Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., & Khorana, H. G. (1996) · Science · doi:10.1126/science.274.5288.768 · Cited by 1,179 · cited 1×
“First, the active, agonist-bound conformation of GPCRs differs from the inactive state, especially in the position of transmembrane helix (TM) 6 (27).”
BackgroundStructure of Bovine Rhodopsin in a Trigonal Crystal Form
Li, J., Edwards, P. C., Burghammer, M., Villa, C., & Schertler, G. F. X. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.08.090 · Cited by 723 · cited 5×
“However, an experimental structure has been obtained only for the inactive state of bovine rhodopsin with bound inverse agonist, 11cisretinal (23,24).”
BackgroundMethodInfluentialSawyer, T. K., Sanfilippo, P. J., Hruby, V. J., Engel, M. H., Heward, C. B., Burnett, J. B., & Hadley, M. E. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.10.5754 · Cited by 575 · cited 1×
“The slightly different orientation for D-Phe7 relative to its L-enatiomer inside the pocket may be responsible for the greater potency and prolonged activity of NDP-MSH, relative toα-MSH (36,50) and for the larger effect of W258A mutation on the binding affinity and potency ofα-MSH relative to NDP-MSH (37).”
BackgroundGantz, I., & Fong, T. M. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00434.2002 · Cited by 466 · cited 5×
“(MC2R), exocrine secretion (MC5R), energy homeostasis, penile erection (MC3R and MC4R) and many others (1,5,6).”
BackgroundMethodInfluentialSelf-citationAgRP(83-132) Acts as an Inverse Agonist on the Human-Melanocortin-4 Receptor
Nijenhuis, W. A. J. (2001) · Molecular Endocrinology · doi:10.1210/me.15.1.164 · Cited by 406
Hrubu, V. J., Lu, D., Sharma, S. D., de L. Castrucci, A., Kesterson, R. A., Al-Obeidi, F. A., Hadley, M. E., & Cone, R. D. (1995) · Journal of Medicinal Chemistry · doi:10.1021/jm00018a005 · Cited by 348
Research works printed but not linked: 44
- Wikberg J. E., 2000, Pharmacol. Res. 42, 393−420.
- Haqq A. M., 2003, Biochem. J., 376
- Van der Ploeg L. H., 2002, Proc. Natl. Acad. Sci. U.S.A. 99
- Yeo G. S., 2003, Hum. Mol. Genet. 12, 561−574.
- Tao Y. X., 2003, Endocrinology 144, 4544−4551.
- Nijenhuis W. A., 2001, Mol. Endocrinol. 15, 164−171.
- Chai B. X., 2003, Peptides 24, 603−609.
- Palucki B. L., 2005, Bioorg. Med. Chem. Lett., 15
- Wisse B. E., 2003, Ann. N.Y. Acad. Sci. 994, 275−281.
- Willoughby C. A., 2002, Bioorg. Med. Chem. Lett., 12, 96
- Palczewski K., 2000, Science 289, 739−745.
- Li J., 2004, J. Mol. Biol., 343
- John B., 2003, Nucleic Acids Res. 31, 3982−3992.
- Farrens D. L., 1996, Science 274, 768−770.
- Halperin I., 2002, Proteins 47, 409−443.
- Pogozheva I. D., 1997, Biophys. J. 72
- Fowler C., 2004, Biochemistry 43, 8700−8710.
- Fowler C. B., 2004, Biochemistry 43, 15796−15810.
- Chai B.-X., 2005, Biochemistry 44, 3418−3431.
- Meng E. C., 2001, Trends Pharmacol. Sci. 22, 587−593.
- Karnik S. S., 2003, Trends Endocrinol. Metab. 14, 431−437.
- Hadley M. E., 1981, Science 213, 1025−1027.
- Yang Y.-K., 2000, Biochemistry 39, 14900−14911.
- Yang Y.-K., 1997, J. Biol. Chem., 272
- DeBlasi A., 1989, Trends Pharmacol. Sci. 10, 227−229.
- Sawyer T. K., 1982, Proc. Natl. Acad. Sci. U.S.A. 79
- Obeidi F., 1989, J. Am. Chem. Soc., 111
- Haskell-Luevano C., 1997, J. Med. Chem., 40
- Sawyer T. K., 1980, Proc. Natl. Acad. Sci. U.S.A. 77
- Prusis P., 1995, Biochem. Biophys. Res. Commun. 210, 205−210.
- Hruby V. J., 1995, J. Med. Chem., 38
- Nikiforovich G. V., 1998, Biopolymers 46, 155−167.
- Ying J., 2003, Biopolymers 71, 696−716.
- Cai M., 2004, J. Pept. Res., 63
- Kask A., 1998, Endocrinology 139, 5006−5014.
- Sugg E. E., 1988, Biochemistry 27, 8181−8188.
- Haskell-Luevano C., 2000, Peptides, 21, 57
- Nijenhuis W. A., 2003, Peptides 24, 271−280.
- Yang Y., 2002, J. Biol. Chem., 277
- Holder J. R., 2002, J. Med. Chem., 45
- Herpin T. F., 2003, Chem. 46, 1123−1126.
- Pan K., 2003, Chem. 11, 185−192.
- Richardson T. I., 2004, J. Med. Chem, 47
- Ballesteros J. A., 1995, Methods Neurosci. 25, 366−428.
Cited by
The Melanocortin-4 Receptor: Physiology, Pharmacology, and Pathophysiology
Tao, Y.-X. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0037 · Cited by 531
“identify how THIQ binds to the MC4R (326, 353, 354).”
BackgroundMutations in ligands and receptors of the leptin–melanocortin pathway that lead to obesity
Farooqi, I. S., & O'Rahilly, S. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0966 · Cited by 291
“Neuropeptide ligands bind to the cavity within the transmembrane bundle and so result in a conformational change and receptor activation”
BackgroundStructure, function and regulation of the melanocortin receptors
Yang, Y. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.12.020 · Cited by 139
“Mutation of these residues to alanine resulted in significantly decrease in endogenous agonist binding and receptor signaling, suggesting that these residues are also involved in melanocortin orthosteric binding (Fleck et al., 2005; Haskell-Luevano et al., 2001; Nickolls et al., 2003; Pogozheva et al., 2005; Yang et a…”
BackgroundInfluentialTargeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction
Wikberg, J. E. S., & Mutulis, F. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2331 · Cited by 139
“Basis for ligand binding Much attention has been given to computational molecular modelling of the melanocortin receptors, but the results are contradictory as the melanocortin binding pocket was placed at grossly different locations in different studie”
ResultEvolution of POMC: origin, phylogeny, posttranslational processing, and the melanocortins
Dores, R. M., & Baron, A. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05928.x · Cited by 127
Structures of active melanocortin-4 receptor–Gs-protein complexes with NDP-α-MSH and setmelanotide
Heyder, N. A., Kleinau, G., Speck, D., Schmidt, A., Paisdzior, S., Szczepek, M., Bauer, B., Koch, A., Gallandi, M., Kwiatkowski, D., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00569-8 · Cited by 102
MOLECULAR EVOLUTION OF GPCRS: Melanocortin/melanocortin receptors
Dores, R. M., Londraville, R. L., Prokop, J., Davis, P., Dewey, N., & Lesinski, N. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0050 · Cited by 92
Tan, K., Pogozheva, I. D., Yeo, G. S. H., Hadaschik, D., Keogh, J. M., Haskell-Leuvano, C., O'Rahilly, S., Mosberg, H. I., & Farooqi, I. S. (2009) · Endocrinology · doi:10.1210/en.2008-0721 · Cited by 91
Self-citationNonpeptidic Ligands for Peptide-Activated G Protein-Coupled Receptors
Blakeney, J. S., Reid, R. C., Le, G. T., & Fairlie, D. P. (2007) · Chemical Reviews · doi:10.1021/cr050984g · Cited by 94
René, P., Gouill, C. L., Pogozheva, I. D., Lee, G., Mosberg, H. I., Farooqi, I. S., Valenzano, K. J., & Bouvier, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.172098 · Cited by 96
Self-citationACTH Receptor (MC2R) Specificity: What Do We Know About Underlying Molecular Mechanisms?
Frīdmanis, D., Roga, A., & Kloviņš, J. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00013 · Cited by 90
“However, work based on the MC4R-binding pocket model (148) partially counters this speculation, because homologous positions of these high effect aromatic residues (F110 and F178) were located in close proximity to aromatic residues of the MC consensus pharmacophore (F235 and W232, respectively), thus indicating their…”
BackgroundMethodResultInfluential60 YEARS OF POMC: Melanocortin receptors: evolution of ligand selectivity for melanocortin peptides
Dores, R. M., Liang, L., Davis, P. V., Thomas, A., & Petko, B. (2016) · Journal of Molecular Endocrinology · doi:10.1530/jme-15-0292 · Cited by 76
Xiang, Z., Proneth, B., Dirain, M. L., Litherland, S. A., & Haskell-Luevano, C. (2010) · Biochemistry · doi:10.1021/bi100068u · Cited by 54
“These data also provide the necessary foundation for computational three-dimensional homologymolecular modeling studies (51, 69) as well as the development of general GPCR algorithms and programs (70) for in silico mutagenesis and predictive approaches for the discovery of those receptor residues that are important fo…”
Linde, Y., Ovadia, O., Safrai, E., Xiang, Z., Portillo, F. P., Shalev, D. E., Haskell‐Luevano, C., Hoffman, A., & Gilon, C. (2008) · Peptide Science · doi:10.1002/bip.21057 · Cited by 53
Functions of transmembrane domain 3 of human melanocortin-4 receptor
Mo, X., Yang, R., & Tao, Y. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0162 · Cited by 50
Dores, R. M. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04434.x · Cited by 49
“…not by α-MSH or any of the other melanocortins.17 These observations mirror the studies done on adrenal cell lines and melanocytes as re- As described in Pogozheva et al., 2005,18 site-directed mutagenesis experiments done on the human MC4R gene revealed residues in transmembrane (TM) regions 2,…”
ResultChen, M., Aprahamian, C. J., Kesterson, R. A., Harmon, C. M., & Yang, Y. (2007) · Biochemistry · doi:10.1021/bi700125e · Cited by 48
Clark, A. J., Forfar, R., Hussain, M., Jerman, J., McIver, E., Taylor, D., & Chan, L. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00101 · Cited by 49
“The interacting aromatic residues of this sequence, Phe 7 and Trp 9 interact with the aromatic Phe at positions 261 and His 264 of MC4R in TM6 (41).”
BackgroundChen, M., Cai, M., Aprahamian, C. J., Georgeson, K. E., Hruby, V., Harmon, C. M., & Yang, Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702285200 · Cited by 45
Kusińska, R., Górniak, P., Pastorczak, A. K., Fendler, W. M., Potemski, P., Mlynarski, W. M., & Kordek, R. (2011) · Molecular Biology Reports · doi:10.1007/s11033-011-1053-2 · Cited by 48
Reinick, C. L., Liang, L., Angleson, J. K., & Dores, R. M. (2012) · Endocrinology · doi:10.1210/en.2012-1482 · Cited by 46
Pleiotropic functions of the transmembrane domain 6 of human melanocortin-4 receptor
Huang, H., & Tao, Y. (2012) · Journal of Molecular Endocrinology · doi:10.1530/jme-12-0161 · Cited by 44
Dores, R. M. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00028 · Cited by 47
“From the perspective of the receptors, Pogozheva et al. (2005) identified critical amino acid positions in transmembrane regions 2, 3, 6, and 7 of human MC4R which are required for activation of that receptor by α-MSH.”
BackgroundJoseph, C. G., Wilson, K. R., Wood, M. S., Sorenson, N. B., Phan, D. V., Xiang, Z., Witek, R. M., & Haskell‐Luevano, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701303z · Cited by 47
Baron, A., Veo, K. D., Angleson, J. K., & Dores, R. M. (2008) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2008.11.026 · Cited by 41
Xiang, Z., Pogozheva, I. D., Sorenson, N. B., Wilczynski, A. M., Holder, J. R., Litherland, S. A., Millard, W. J., Mosberg, H. I., & Haskell-Luevano, C. (2007) · Biochemistry · doi:10.1021/bi7007382 · Cited by 40
Self-citationMolecular signatures of human melanocortin receptors for ligand binding and signaling
Yang, Y., & Harmon, C. M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.04.025 · Cited by 44
Inhibition of melanocortin-4 receptor dimerization by substitutions in intracellular loop 2
Piechowski, C. L., Rediger, A., Lagemann, C., Mühlhaus, J., Müller, A., Pratzka, J., Tarnow, P., Grüters, A., Krude, H., Kleinau, G., et al. (2013) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0061 · Cited by 46
“Of note, it was reported in previous studies that specific amino acids in TMH3 are significant for MC4R function, including Asp122 and Asp125 (Pogozheva et al. 2005).”
ResultIdentification of Three Novel Genetic Variants in the Melanocortin‐3 Receptor of Obese Children
Zegers, D., Beckers, S., de Freitas, F., Peeters, A. V., Mertens, I. L., Verhulst, S. L., Rooman, R., Timmermans, J., Desager, K., Massa, G., et al. (2011) · Obesity · doi:10.1038/oby.2010.127 · Cited by 40
“This histidine residue has been demonstrated to be essential for melanocortin peptide activation of MC4R and to be important for interaction with γ-MSH (35).”
BackgroundInfluentialBiased Signaling in Naturally Occurring Mutations in Human Melanocortin-3 Receptor Gene
Yang, F., Huang, H., & Tao, Y. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.11032 · Cited by 38
Liang, L., Angleson, J. K., & Dores, R. M. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2012.11.011 · Cited by 35
Yu, S., Yuan, J., Shi, J., Ruan, X., Zhang, T., Wang, Y., & Du, Y. L. (2015) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2015.04.017 · Cited by 35
Molecular and Functional Analysis of Human β-Defensin 3 Action at Melanocortin Receptors
Nix, M. A., Kaelin, C. B., Ta, T., Weis, A., Morton, G. J., Barsh, G. S., & Millhauser, G. L. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.04.015 · Cited by 34
“edu/ resources/ (Chai et al., 2005; Pogozheva et al., 2005).”
Davis, P. V., Franquemont, S., Liang, L., Angleson, J. K., & Dores, R. M. (2013) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2013.04.007 · Cited by 32
Falls, B. A., & Zhang, Y. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00346 · Cited by 29
Modeling Molecular Mechanisms of Binding of the Anaphylatoxin C5a to the C5a Receptor
Nikiforovich, G. V., Marshall, G. R., & Baranski, T. (2008) · Biochemistry · doi:10.1021/bi702321a · Cited by 27
Proneth, B., Xiang, Z., Pogozheva, I. D., Litherland, S. A., Gorbatyuk, O. S., Shaw, A. M., Millard, W. J., Mosberg, H. I., & Haskell‐Luevano, C. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00362.x · Cited by 33
Self-citationWichard, J., ter Laak, A., Krause, G., Heinrich, N., Kühne, R., & Kleinau, G. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016811 · Cited by 28
Barlock, T. K., Gehr, D. T., & Dores, R. M. (2014) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2014.03.045 · Cited by 28
Reinick, C. L., Liang, L., Angleson, J. K., & Dores, R. M. (2012) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.01.021 · Cited by 25
Design, Synthesis and Biological Evaluation of Ligands Selective for the Melanocortin-3 Receptor
Hruby, V. J., Cai, M., Cain, J. P., Mayorov, A. V., Dedek, M. M., & Trivedi, D. B. (2007) · Current Topics in Medicinal Chemistry · doi:10.2174/156802607780906645 · Cited by 29
“Molecular modeling provides a rationale for the activity of this molecular template, as the pharmacophore elements found in the small molecules appear to overlap with the side-chain functionality found in the key residues of bioactive peptide ligands [79].”
BackgroundClick-Chemistry-Mediated Synthesis of Selective Melanocortin Receptor 4 Agonists
Palmer, D., Gonçalves, J. P. L., Hansen, L. V., Wu, B., Hald, H., Schoffelen, S., Diness, F., Quement, S. T. L., Nielsen, T. E., & Meldal, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00353 · Cited by 26
Liang, L., Reinick, C. L., Angleson, J. K., & Dores, R. M. (2012) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2012.08.016 · Cited by 23
Interactions of the Melanocortin-4 Receptor with the Peptide Agonist NDP-MSH
Chapman, K. L., Kinsella, G. K., Cox, A., Donnelly, D., & Findlay, J. B. C. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.06.028 · Cited by 24
Dores, R. M. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00079 · Cited by 24
“amino acids in the proposed HFRW-binding site (47) is marked with a star.”
BackgroundInfluentialKim, J. H., Lee, J.-E., Kim, T., Yeom, M. H., Park, J. S., di Luccio, E., Chen, H., Dong, Z., Lee, K. W., & Kang, N. J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.577284 · Cited by 21
“First, the sequence based search showed that MC1R has a similarity of 47% with a MC4R theoretical model (PDB entry: 2IQP) (Pogozheva et al., 2005), then the MC1R structure was built by using Prime v3.”
MethodMelanocortin Peptide Therapy for the Treatment of Arthritic Pathologies
Getting, S. J., Kaneva, M. K., Bhadresa, Y., Renshaw, D. W., Leoni, G., Patel, H., Kerrigan, M. J. P., & Locke, I. C. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.163 · Cited by 21
Yang, Y., Cai, M., Chen, M., Qu, H., McPherson, D. T., Hruby, V. I., & Harmon, C. M. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.006 · Cited by 22
“Previously, Pogozheva et al reported that THIQ shares somebinding sites with NDP-MSH at hMC4R using hypothesis-driven selection of receptor amino acid residue for site-directed mutagenesis study [32].”
InfluentialProneth, B., Pogozheva, I. D., Portillo, F. P., Mosberg, H. I., & Haskell‐Luevano, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800291b · Cited by 22
Self-citationJanovick, J. A., Pogozheva, I. D., Mosberg, H. I., & Conn, P. M. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180869 · Cited by 19
“The models were generated as described previously for melanocortin receptors (Chai et al., 2005; Pogozheva et al., 2005).”
MethodSelf-citationTokimoto, T., Bethea, T. R. C., Zhou, M., Ghosh, I., & Wirth, M. J. (2007) · Applied Spectroscopy · doi:10.1366/000370207779947512 · Cited by 19
Observations on the ligand selectivity of the melanocortin 2 receptor
Veo, K., Reinick, C., Liang, L., Moser, E., Angleson, J. K., & Dores, R. M. (2011) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2011.04.006 · Cited by 18
From Bioinactive ACTH to ACTH Antagonist: The Clinical Perspective
Ghaddhab, C., Vuissoz, J., & Deladoëy, J. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00017 · Cited by 23
Molecular characterization of human melanocortin-5 receptor ligand-receptor interaction
Yang, Y., Mishra, V. K., Chen, M., Duffee, E., Dimmitt, R., & Harmon, C. M. (2013) · Biochemistry · doi:10.1021/bi3013593 · Cited by 17
Grieco, P., Brancaccio, D., Novellino, E., Hruby, V. J., & Carotenuto, A. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.038 · Cited by 121
“(b) Bottom stereoview of MTII and NDP-MSH within the binding pocket of h-MC4Ra.”
BackgroundMethodInfluentialKontijevskis, A., Petrovska, R., Mutule, I., Uhlén, S., Komorowski, J., Prūsis, P., & Wikberg, J. E. S. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21461 · Cited by 15
Alfieri, A., Pasanisi, F., Salzano, S., Esposito, L., Martone, D., Tafuri, D., Daniele, A., Contaldo, F., Sacchetti, L., Zagari, A., et al. (2010) · Gene · doi:10.1016/j.gene.2010.03.001 · Cited by 16
Molecular determinants of ACTH receptor for ligand selectivity
Yang, Y., & Harmon, C. M. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110688 · Cited by 17
Dores, R. M., & Chapa, E. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.747843 · Cited by 16
“An alignment of the primary sequences of esMC2R and hMC2R (39) indicated that the critical residues associated with the HFRW binding site [see (46)] in transmembrane domains 2,3 and 6 are all present in bothMC2R orthologs, yet the two receptors react to stimulation by aMSH in striking different ways.”
BackgroundChen, M., Cai, M., McPherson, D. T., Hruby, V. J., Harmon, C. M., & Yang, Y. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.023 · Cited by 15
“have modeled both the active and inactive states of hMC4R and propose that TMs movement accompany MC4R activation [57].”
3Recent Progress Toward Nonpeptide Ligands for the Melanocortin-4 Receptor
Chen, C. (2007) · Progress in medicinal chemistry · doi:10.1016/s0079-6468(06)45503-x · Cited by 14
der Poorten, O. V., Fehér, K., Buysse, K., Feytens, D., Zoi, I., Schwartz, S. D., Martins, J. C., Tourwé, D. A., Cai, M., Hruby, V. J., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500436s · Cited by 13
Analyzing the activation of the melanocortin-2 receptor of tetrapods
Dores, R. M., & Liang, L. (2014) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2014.03.039 · Cited by 11
Wang, Z.-Q., Wang, W., Shi, L., Chai, J.-T., Zhang, X., & Tao, Y. (2016) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2016.02.016 · Cited by 8
Davis, P. E., Wilkinson, E. C., & Dores, R. M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174166 · Cited by 8
“Note that six of the critical residues that formed the HFRW binding site in hMC4R [10] are in nearly the same position in or near the TM2 and TM3 domain, and in or near the TM6 domain of the three MC2R orthologs.”
BackgroundMethodInfluentialChen, M., Georgeson, K. E., Harmon, C. M., Haskell‐Luevano, C., & Yang, Y. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.012 · Cited by 7
Homology Modeling and Ligand-Based Molecule Design
Sun, H. (2015) · Elsevier eBooks · doi:10.1016/b978-0-08-100098-4.00004-1 · Cited by 6
Davis, P. V., Shaughnessy, C. A., & Dores, R. M. (2022) · Biomolecules · doi:10.3390/biom12101422 · Cited by 5
“, [21] on the HFRW binding site for hMC4R, w ich was confirmed by x-ray crystallographic analysis [22], Chen et al.”
MethodA 3D model for human melanocortin 4 receptor refined with molecular dynamics simulation
Shahlaei, M., & Mousavi, A. (2014) · Journal of Reports in Pharmaceutical Sciences · doi:10.4103/2322-1232.222547 · Cited by 5
Yang, Y., Chen, M., Dimmitt, R. A., & Harmon, C. M. (2014) · Biochemistry · doi:10.1021/bi500856x · Cited by 6
Amino acid residue L112 in the ACTH receptor plays a key role in ACTH or α-MSH selectivity
Yang, Y., Chen, M., Ventro, G. J., & Harmon, C. M. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.12.002 · Cited by 5
Liang, L., Davis, P. V., Dores, M. R., & Dores, R. M. (2017) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2017.05.003 · Cited by 4
“The positions marked with a * (i.e., E 80 , D 104 , D 107 , W 232 , F 235 , H 238 ) indicate residues 368 that are also found in hMC4R that have been shown to be in the HFRW binding site of hMC4R 369 (Pogozheva et al., 2005).”
BackgroundComputer-Aided Identification of Ligands for GPCR Anti-Obesity Targets
Min, K. H., Yoo, J., & Park, H. (2009) · Current Topics in Medicinal Chemistry · doi:10.2174/156802609788897871 · Cited by 4
Hoglin, B. E., Miner, M. V., Erdenebayar, U., Shaughnessy, C. A., & Dores, R. M. (2023) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2023.114278 · Cited by 3
Shaughnessy, C. A., Le, K. M., Myhre, V. D., & Dores, R. M. (2023) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2023.114356 · Cited by 3
Azepinone-Constrained Amino Acids in Peptide and Peptidomimetic Design
Ballet, S., Guillemyn, K., der Poorten, O. V., Schurgers, B., Verniest, G., & Tourwé, D. A. (2015) · Topics in heterocyclic chemistry · doi:10.1007/7081_2015_161 · Cited by 3
Key amino acid residue in Melanocortin-1 receptor (melanocyte α-MSH receptor) for ligand selectivity
Yang, Y., Chen, M., Ventro, G. J., & Harmon, C. M. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.05.038 · Cited by 4
Descriptive analysis of MC4R gene variants associated with obesity listed on ClinVar
Bayhaghi, G., Karim, Z. A., & Silva, J. (2024) · Science Progress · doi:10.1177/00368504241297197 · Cited by 2
Integrative molecular characterization and in silico analyses of caprine MC3R, MC4R, and MC5R genes
Venkatesh, K. M., Mishra, C., & Pradhan, S. K. (2022) · Small Ruminant Research · doi:10.1016/j.smallrumres.2022.106812 · Cited by 1
Modeling the interactions between MC2R and ACTH models from human
Mutangana, D., & Ramesh, K. V. (2014) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2014.910475 · Cited by 2
“Based on modeling and sitedirected mutagenesis of human MC4R, binding site of this receptor has been characterized (Pogozheva et al., 2005).”
BackgroundProneth, B., Portillo, F. P., & Haskell‐Luevano, C. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-73657-0_142 · Cited by 1
Marinkovic, D., Tucci, F. C., Tran, J. A., Fleck, B. A., Wen, J., & Chen, C. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.07.076 · Cited by 1
Hormones, 2. Peptides and Proteins: Hypothalamic–Pituitary and Calcitropic Hormones
Sandow, J. (2013) · Wiley eBooks · doi:10.1002/14356007.a19_061.pub2 · Cited by 1
Computational Modeling of Constitutively Active Mutants of GPCRs
Nikiforovich, G. V., & Baranski, T. (2010) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-381296-4.00021-x · Cited by 1
ACTH, Melanocortin Receptors, and MRAP Accessory Proteins
Dores, R. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95733-7 · Cited by 1
Subtype selective activation and molecular characterization of galanin receptors
Lundström, L. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Molekulare Charakterisierung an der hypothalamischen Appetitregulation beteiligter Rezeptoren
Fakultät, D. D. M.-N., & Schön, L.-H. (2008)
ACTH, melanocortin receptors, and MRAP accessory proteins
Dores, R. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00145-x
Des toxines animales comme ligands innovants des récepteurs aux mélanocortines
Reynaud, S. (2019) · theses.fr (ABES) · doi:10.70675/3b7e4bedz99ffz4cbaz82c0za19291184a87
BindingDB (2019) · UC San Diego · doi:10.7270/q2vq3535
Metadata
- Authors
- Pogozheva, I. D., Chai, B.-X., Lomize, A. L., Fong, T. M., Weinberg, D. H., Nargund, R. P., Mulholland, M. W., Gantz, I., & Mosberg, H. I.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2005-08-01
- Volume
- 44
- Issue
- 34
- Pages
- 11329-11341
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- PMC
- PMC2532597
- OpenAlex
- W1995624852
- Cited by
- 92
- References
- 81
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 8 · 2016: 4 · 2015: 4 · 2014: 7 · 2013: 7 · 2012: 7
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- University of Michigan
- National Institute on Drug Abuse (R01DA003910, DA03910)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK034933, P30 DK 34933, R01DK054032, DK054032)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- melanocortin-4 receptor, ligand-receptor interactions, peptide agonists, NDP-MSH, alanine scanning, transmembrane helices, disulfide bonds, pharmacophore, binding affinity, agonist potency
- MeSH terms
- Cyclic AMP, Amino Acid Sequence, Binding Sites, Humans, Models, Molecular, Molecular Sequence Data, Peptides, Piperazines, Piperidines, Recombinant Proteins, Rhodopsin, Transfection, Mutagenesis, Site-Directed, Sequence Alignment, Sequence Homology, Amino Acid, Protein Structure, Secondary, Receptor, Melanocortin, Type 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.